Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.

Abstract

The authors report further analysis of a six-year retrospective chart review of multiple sclerosis (MS) patients prescribed interferon-beta (IFNB) in British Columbia, Canada. Actions and outcomes taken when 284/835 (34%) of the patients developed de novo elevated aminotransferases are presented; 239/284 (84%) of patients were continued on treatment despite these elevations; 216/246 (88%) of patients reaching grade 1 toxicity (greater than the upper limit of normal) continued IFNB treatment; of these, 167/216 (77%) returned to within normal limits. Of the 22/29 (76%) reaching grade 2 toxicity (> 2.5 times the upper limit of normal) and continuing treatment, 14/22 (64%) returned to within the normal range. One of the nine patients reaching grade 3 toxicity ( > 5 times the upper limit of normal) was allowed continue treatment and their aminotransferase levels returned to within normal limits. However, one patient reaching grade 3 toxicity went on to develop liver failure (previously reported).

Statistics

050100'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

128 Citations

Semantic Scholar estimates that this publication has 128 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Tremlett2004ElevatedAD, title={Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.}, author={Helen L Tremlett and Joel J F Oger}, journal={Multiple sclerosis}, year={2004}, volume={10 3}, pages={298-301} }